

#2
Dw
4/3/00

IN THE UNITED STATES PATENT OFFICE

Application Serial No. 09/465,338

Our Ref.: PT1817

Filing Date: December 17, 1999

Applicants : BIOVAIL
LABORATORIES
INCORPORATED

Agent: Ivor M. Hughes,
Suite 200,
175 Commerce Valley
Drive West,
Thornhill, Ontario
Canada L3T 7P6

Title : CHRONOTHERAPEUTIC
FORMULATIONS OF DILTIAZEM
AND THE ADMINISTRATION THEREOF

Inventors : Kenneth Stephen Albert
Paul José Maes

INFORMATION DISCLOSURE STATEMENT

March 24, 2000

The Commissioner of Patents
UNITED STATES PATENT OFFICE
2011 South Clark Place
Crystal Plaza 2, Room 1B03
Arlington, Virginia 22202 U.S.A.

Dear Sir:

Applicants and the undersigned are aware of "patents, publications, or other information" which they believe may be material to the examination of the above-identified application. Four sheets of Form PTO-1449 listing all items, are submitted herewith pursuant to 37 C.F.R. §§ 1.97-1.99 and to the duty of disclosure set forth in 37. C.F.R. § 1.56. Copies of the six journal articles and EP 0856313, WO 93/00093, WO 93/09767, EP 0605174 and EP 0282698 are enclosed. All other documentation is printed in English, and accordingly, is not enclosed.

Please advise Applicant's agent should you require copies of all items cited
03/30/2000 PDELRTC 00000008 09465338
01 FC:126 herein. Applicant encloses the fee for filing an information disclosure statement

in the sum of \$240.00 U.S. funds. If there is any deficiency or surplusage of the fee enclosed for the information disclosure statement, please obtain any such deficiency or credit the surplusage to Deposit Account 08-3255 and advise Applicant's Agent.

Although this Information Disclosure Statement identifies references which may be "material," it is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" (within the meaning of 35 U.S.C. §102 and §103) as to the invention disclosed and claimed in this application unless specifically designated as such. Moreover, no representation is intended as to the relative relevance of any portion of the references or as to the relevance among references, whether cited in this Statement or elsewhere.

In accordance with 37 C.F.R. §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a novelty search has been made or that no other information which may be material (as defined in 37 C.F.R. §1.56(a)) exists.

UNITED STATES PATENT DOCUMENTS

4,263,273
4,327,725
4,600,645
4,612,008
4,623,588
4,696,924
4,705,695
4,721,619
4,753,802
4,783,337
4,784,858
4,792,452

4,808,413
4,824,678
4,832,958
4,839,177
4,859,469
4,859,470
4,880,631
4,891,230
4,894,240
4,917,899
4,938,967
4,940,588
4,952,402
4,960,596
4,966,769
5,000,962
5,002,776
5,004,614
5,008,114
5,051,262
5,082,668
5,112,621
5,149,542
5,156,850
5,160,744
5,175,003
5,178,867
5,190,765
5,219,621
5,229,135
5,252,338
5,260,068
5,260,069
5,275,824
5,286,497
5,288,505
5,326,571
5,330,761
5,336,504
5,344,657
5,354,556
5,364,620
5,419,917
5,439,689
5,445,829
5,449,521
5,455,046
5,458,887
5,458,888
5,464,633
5,470,584
5,472,708
5,472,711
5,478,574
5,508,040
5,512,297
5,529,790
5,529,791

5,554,387
5,558,879
5,567,441
5,601,845
5,616,345
5,622,716
5,626,860
5,654,005
5,662,933
5,667,801
5,670,168
5,670,172
5,681,583
5,688,794
5,716,933
5,716,962
5,736,159
5,756,513
5,773,025
5,785,994
5,830,503
5,834,023
5,834,024
5,837,379
5,840,329
5,843,347
5,846,563
5,851,555
5,869,097
5,914,134
5,916,595
5,922,352
5,945,125
5,958,456
6,004,582
6,022,562
6,033,687
Re. 35,903

FOREIGN PATENT DOCUMENTS

EP 0 149 920 A2
EP 0 263 083 A1
EP 0 282 698 A
EP 0 309 051 A1
EP 0 315 414 A1
EP 0 318 398 A1
EP 0 320 097 A1
EP 0 322 277 A1
EP 0 340 105 A1
EP 0 342 106 A1
EP 0 373 417 A1
EP 0 527 637 B1
EP 0 591 424 B1
EP 0 605 174 A
EP 0 682 945 B1
EP 0 856 313 A1

WO 90/06107
WO 91/01722
WO 93/00093
WO 93/09767
WO 96/29992
WO 97/23219
WO 97/48386
WO 98/32424
WO 98/33488
WO 98/33489

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Deedwanian, C. et al., *Effect of Morning Versus Evening Dosing of Diltiazem on Myocardial Ischemia Detected by Ambulatory Electrocardiographic Monitoring in Chronic Stable Angio Pectoris*, PRA KASH, The American Journal of Cardiology, Vol. 80, Aug. 15, 1997, p. 421-425

Kelly, J.G. et al., *Pharmacokinetic Properties and Antihypertensive Efficacy of Once-Daily Diltiazem*, Journal of Cardio-Vascular Pharmacology, 17:6:957-963, (1991)


Kohno, I. et al., *Administration Time - Dependent Effects of Diltiazem on The 24-Hour Blood Pressure Profile of Essential Hypertension Patients*, Chronobiology International, 14(1), 71-84, (1997)

Leeuwenkamp, O.R. et al, *A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets*, Eur. J. Clin. Pharmacol., (1994) 46:243-247

Thiffault, J. et al., *The Influence of Time Administration on the Pharmacokinetics of a Once A Day Diltiazem Formulation: Morning Against Bedtime*, Biopharmaceutics & Drug Disposition, Vol. 17, 107 - 115 (1996)

Zahirul, M. et al., *Recent Trends and Progress in Substained or Controlled Oral Delivery of Some Water Soluble Drugs: Morphine Salts, Diltiazem and Captopril*, Drug Development and Industrial Pharmacy, US, New York, NY, vol. 21, no. 9, 1 January 1995, pages 1037-1070

Respectfully submitted,
IVOR M. HUGHES


Avor M. Hughes
Registration #27,759
Agent for Applicant


Marcelo K. Sarkis
Registration #37,015
Agent for Applicant